Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3284
Name thymic carcinoma
Definition A thymus cancer that derives_from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer immune system cancer thymus cancer thymic carcinoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT D579del Imatinib thymic carcinoma sensitive detail...
KIT Y553N Imatinib thymic carcinoma sensitive detail...
KIT V560del KIT over exp Imatinib thymic carcinoma predicted - sensitive detail...
KIT P577_D579del Sorafenib thymic carcinoma predicted - sensitive detail...
KIT D820E Sorafenib thymic carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01011439 Phase II Milciclib Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Terminated USA | ITA | FRA 0
NCT01025089 Phase II Cetuximab Cisplatin + Cyclophosphamide + Doxorubicin Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting USA 0
NCT01301391 Phase II Milciclib Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated USA | ITA 0
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT01621568 Phase II Sunitinib Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting USA 0
NCT02364076 Phase II Epacadostat + Pembrolizumab Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Unknown status USA 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | FRA | ESP | BEL | AUS 1
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT03076554 Phase II Avelumab A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 4
NCT03134118 Phase II Nivolumab Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM) Active, not recruiting GBR | FRA | ESP | BEL 2
NCT03193437 Phase II Selinexor Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Terminated USA 0
NCT03295227 Phase I Pembrolizumab Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting USA 0
NCT03449173 Phase II Sunitinib Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) (Style) Unknown status ITA 0
NCT03463460 Phase II Pembrolizumab + Sunitinib Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 0
NCT03583086 Phase Ib/II Nivolumab + Vorolanib H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Active, not recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA 0
NCT03694002 Phase II Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Ramucirumab Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT04417660 Phase II Bintrafusp alfa Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting USA 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04710628 Phase II Lenvatinib + Pembrolizumab Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI) Recruiting ITA | FRA | ESP 0
NCT04925947 Phase II KN046 Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors Terminated USA 0
NCT05544929 Phase I KFA115 + Tislelizumab KFA115 A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers Recruiting USA | CAN 4